Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Nov;28(5):551–554. doi: 10.1111/j.1365-2125.1989.tb03541.x

Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

H Perrild 1, L Kayser 1, H E Poulsen 1, L Skovsted 1, B Jørgensen 1, J M Hansen 1
PMCID: PMC1380015  PMID: 2574053

Abstract

1. Antipyrine (1000 mg orally) clearance was studied 3 days before treatment with either atenolol (50 mg twice daily), metoprolol (100 mg twice daily), propranolol (80 mg twice daily) or placebo, and at day 5 and 18 during treatment. Phenytoin (100 mg intravenously) clearance was measured on days 0, 7 and 21 during treatment. 2. Antipyrine clearance was decreased by about 20% after 5 days of treatment with either propranolol or atenolol and this decrease persisted after 18 days of treatment. Antipyrine clearance did not change during treatment with either metoprolol or placebo. Phenytoin clearance did not change during any of the treatments.

Full text

PDF
551

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bax N. D., Jones R. W., Lennard M. S., Tucker G. T., Woods H. F. Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man. Br J Clin Pharmacol. 1985 May;19(5):593–596. doi: 10.1111/j.1365-2125.1985.tb02685.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bax N. D., Lennard M. S., Tucker G. T. Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol. 1981 Dec;12(6):779–784. doi: 10.1111/j.1365-2125.1981.tb01306.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clark D. W. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs. 1985 Apr;29(4):342–375. doi: 10.2165/00003495-198529040-00003. [DOI] [PubMed] [Google Scholar]
  4. Daneshmend T. K., Roberts C. J. The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects. Br J Clin Pharmacol. 1982 Jun;13(6):817–820. doi: 10.1111/j.1365-2125.1982.tb01872.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Døssing M., Pilsgaard H., Rasmussen B., Poulsen H. E. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol. 1983;25(2):215–222. doi: 10.1007/BF00543794. [DOI] [PubMed] [Google Scholar]
  6. Døssing M., Vølund A., Poulsen H. E. Optimal sampling times for minimum variance of clearance determination. Br J Clin Pharmacol. 1983 Feb;15(2):231–235. doi: 10.1111/j.1365-2125.1983.tb01491.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Greenblatt D. J., Franke K., Huffman D. H. Impairment of antipyrine clearance in humans by propranolol. Circulation. 1978 Jun;57(6):1161–1164. doi: 10.1161/01.cir.57.6.1161. [DOI] [PubMed] [Google Scholar]
  8. Hansen J. M., Kristensen M., Skovsted L. Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism. Epilepsia. 1968 Mar;9(1):17–22. doi: 10.1111/j.1528-1157.1968.tb04954.x. [DOI] [PubMed] [Google Scholar]
  9. Lumholtz B., Siersbaek-Nielsen K., Skovsted L., Kampmann J., Hansen J. M. Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. Clin Pharmacol Ther. 1975 Jun;17(6):731–734. doi: 10.1002/cpt1975176731. [DOI] [PubMed] [Google Scholar]
  10. Mølholm Hansen J., Skovsted L., Kampmann J. P., Lumholtz B. I., Siersbaek-Nielsen K. Unaltered metabolism of phenytoin in thyroid disorders. Acta Pharmacol Toxicol (Copenh) 1978 May;42(5):343–346. doi: 10.1111/j.1600-0773.1978.tb02214.x. [DOI] [PubMed] [Google Scholar]
  11. Perrild H., Hansen J. M., Skovsted L., Christensen L. K. Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism. Clin Endocrinol (Oxf) 1983 Feb;18(2):139–142. doi: 10.1111/j.1365-2265.1983.tb03196.x. [DOI] [PubMed] [Google Scholar]
  12. Pilsgaard H., Poulsen H. E. A one-sample method for antipyrine clearance determination in rats. Pharmacology. 1984;29(2):110–116. doi: 10.1159/000137999. [DOI] [PubMed] [Google Scholar]
  13. Poulsen H. E., Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol. 1988 Jun;6(3):374–382. doi: 10.1016/s0168-8278(88)80057-6. [DOI] [PubMed] [Google Scholar]
  14. Sloan T. P., Idle J. R., Smith R. L. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther. 1981 Apr;29(4):493–497. doi: 10.1038/clpt.1981.68. [DOI] [PubMed] [Google Scholar]
  15. Tucker G. T., Bax N. D., Lennard M. S., Crewe K., Woods H. F. Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol. 1982 Nov;14(5):743–744. doi: 10.1111/j.1365-2125.1982.tb04967.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES